GlassScriptPhysician profile
Tracie Malsom
NPI 1720038441
$2,179.56
in general payments reported to CMS, 2019-2025
21 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $216 · 2021: $527 · 2022: $450 · 2023: $230 · 2024: $188 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $435.45 | 2019-2025 | Clareon, Rocklatan |
| Sun Pharmaceutical Industries INC. | $394.27 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $366.80 | 2020-2025 | Acthar |
| Allergan, INC. | $222.93 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $194.66 | 2020-2023 | |
| Biotissue Holdings INC. | $112.76 | 2022-2025 | |
| Abbvie INC. | $66.49 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $59.11 | 2019 | |
| Rxsight INC | $50.01 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Aerie Pharmaceuticals, INC. | $46.75 | 2020-2021 | |
| Dompe US, INC. | $39.71 | 2020-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $29.75 | 2025 | Purified Cortrophin Gel |
| Ocular Therapeutix, INC. | $27.64 | 2023-2025 | Dextenza |
| Harrow Eye, LLC | $24.22 | 2025 | Vevye |
| Coopervision INC. | $18.82 | 2025 | Misight Contact Lens |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.40 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $16.27 | 2020 | |
| Astellas Pharma US INC | $14.95 | 2023 | |
| Oyster Point Pharma, INC. | $14.16 | 2022 | |
| Amgen INC. | $14.05 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie Malsom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.